Dr. Michael Har-Noy Compares Checkpoint Blockade To AlloStimTM

29 Jul

Dr. Michael Har-Noy of Immunovative Therapies, Ltd. says that checkpoint blockade compoiunds block a molecule used by tumor cells to turn off immune cells that are primed and ready to kill. Yervoy blocks the molecule CTLA-4 and Opdivo blocks a molecule named PD-1. When these molecules are neutralized, immune cells can see and kill the cancer cells.

However, Dr. Michael Har-Noy says that these blockade drugs only work if the patient has an intact immune response that can eliminate the cancers. Most cancer patients have an ineffective immune response and for this reason the response rates of checkpoint blockade compounds has been poor and is restricted to cancers, such as melanoma, that are very immunogenic.

Dr. Michael Har-Noy has created an innovative technology that may be effective in treating most types of tumors and infectious diseases. This technology is completely different from previously tested immunotherapies. Instead of being conceptualized first in animals and then in humans, Dr. Michael Har-Noy’s unique platform was reverse engineered from a known human immune response that has already been shown to be capable of eradicating chemotherapy-resistant metastatic tumors and that has been curative in many instances.

The immune reaction resulting from the transplantation of a person’s immune cells (adult stem cells) into a cancer patient has been described as the most potent anti-tumor mechanism ever discovered. Dr. Michael Har-Noy says that this reaction, called the “graft vs. tumor” effect or “GVT”, is the only known mechanism that can, without surgery, debulk chemotherapy-resistant metastatic cancer. However, the clinical utility of the GVT effect is drastically limited due to its often lethal complication called “graft vs. host disease” or “GVHD” which is closely associated with the GVT cascade. The separation of the curative GVT mechanism from the detrimental GVHD effect has been referred to as the “holy grail” of transplantation. Dr. Michael Har-Noy has synthesized a compound called AlloStimTM that uses the proprietary “Mirror EffectTM” technology to mimic the curative effect of a transplant without GVHD toxicity

Advertisements
%d bloggers like this: